Prima's DCtag technology -- broad spectrum vaccine technology against cancer, parasitic and viral diseases

摘要

Prima Biomed Limited (ASX: PRR) recently announces the final and excellent results from the first stage of the development of its DCtag vaccine technology, being developed by subsidiary Panvax Ltd. DCtag is a unique nanoparticle with demonstrated ability to protect animals against lethal malaria parasites and to provide an effective immunotherapy treatment against established tumors in mice, leading to eradication of the tumors. Apart from previous results over the last 18 months, experiments have been performed to ascertain if DCtag could be coupled to a range of proteins found in human cancers and to viral proteins from a respiratory virus and similarly stimulate strong immune responses and prevent such diseases in mice.